Taylor Morrison (TMHC) Shares Down 5.3%

Evarado Alatorre
May 16, 2018

Taylor Morrison Home Corporation (TMHC) has $2.50B valuation. The stock traded volume of 459270 shares in last session versus to an average volume of 1196.25K shares.

Notwithstanding that, the passion for the stock has decreased, which sees decrease in its trading volume by -21.04% below its longer-run average levels. (OTCMKTS:PTOTF) has 0.00% since May 15, 2017 and is. It has underperformed by 2.53% the S&P500. It's down -0.11, from 1.73 in 2017Q3.

Taylor Morrison (NYSE:TMHC) last announced its quarterly earnings data on Wednesday, May 2nd. They expect $0.48 EPS, up 4.35% or $0.02 from last year's $0.46 per share. TMHC's profit will be $53.85 million for 11.62 P/E if the $0.48 EPS becomes a reality. Inc. lifted its holdings in shares of Taylor Morrison by 39.2% during the first quarter.

Investors sentiment increased to 1.48 in Q4 2017.

Institutional investors and hedge funds have recently bought and sold shares of the business. 38 funds opened positions while 60 raised stakes. Ameritas Prtn owns 6,849 shares or 0.01% of their USA portfolio.

TMHC has been the topic of several other research reports. Hanson Mcclain holds 200 shares or 0% of its portfolio. Taylor Morrison Home Corporation (NYSE:TMHC) at the moment has a 10-month price index of 0.92. Fny Managed Accounts reported 174 shares. Gsa Prns Ltd Liability Partnership holds 49,571 shares. Laurion Mgmt L P has 0.09% invested in Taylor Morrison Home Corporation (NYSE:TMHC) for 730,211 shares. Stone Ridge Asset Mngmt Limited Liability has invested 0.08% of its portfolio in Taylor Morrison Home Corporation (NYSE:TMHC). Ubs Asset Mngmt Americas stated it has 45,133 shares or 0% of all its holdings. Stanley has invested 0.2% in Taylor Morrison Home Corporation (NYSE:TMHC). Therefore 54% are positive.

More news: Storm hits Delhi-NCR, Met department issues warning in nearby areas

Taylor Morrison Home Corporation operates as a public homebuilder in the United States. The company has an average rating of "Buy" and an average price target of $28.63. Taylor Morrison Home Corporation had 36 analyst reports since August 6, 2015 according to SRatingsIntel. Deutsche Bank upped their target price on Taylor Morrison from $27.00 to $28.00 and gave the company a "buy" rating in a report on Friday, February 23rd. The firm has "Neutral" rating by B. Riley & Co given on Thursday, February 8. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Barclays Capital has "Equal-Weight" rating and $28 target.

Investors have placed Taylor Morrison Home Corporatio (TMHC) shares on watch as the Aroon Down indicator has moved above 70, indicating that there is downward momentum building for the shares. The company was maintained on Friday, April 28 by FBR Capital. TPG Group Holdings (SBS) Advisors - Inc. also sold $40.70M worth of Taylor Morrison Home Corporation (NYSE:TMHC) on Wednesday, January 17.

In other Taylor Morrison news, insider Joseph Terracciano sold 5,788 shares of the company's stock in a transaction that occurred on Tuesday, February 20th.

Analysts await TherapeuticsMD, Inc. After $0.41 actual earnings per share reported by Taylor Morrison Home Corporation for the previous quarter, Wall Street now forecasts 17.07% EPS growth. -21.50% away from the high and 13.36% from the low. About 1.77 million shares traded. TherapeuticsMD, Inc. (TXMD) has declined 30.29% since May 15, 2017 and is downtrending.

The firm holds a gross margin of 19.10% and a price to earnings ratio of 47.47. The Company's pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. Moreover, Ardsley Advisory Partners has 0.77% invested in the company for 1.05 million shares.

The stock's Average True Range for 14 days was 0.71.

Otros informes por

Discuta este artículo